A micro-imaging study linking bone cancer pain with tumor growth and bone resorption in a rat model

Clinical and Experimental Metastasis

Volumn 30, Issue 2, 2013, Pages 225-236

  Doré Savard, Louis ^a   Beaudet, Nicolas ^a   Tremblay, Luc ^a   Xiao, Yongjun ^b   Lepage, Martin ^a   Sarret, Philippe ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Allodynia; Dynamic weight bearing; Metastasis; Micro CT; MRI

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; BONE CANCER; BONE MASS; BONE METASTASIS; BONE REMODELING; BREAST CARCINOMA; CANCER PAIN; CARCINOMA CELL; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CORTICAL BONE; FEMUR; HUMAN; HYPERSENSITIVITY; MALE; MECHANICAL STIMULATION; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OSTEOLYSIS; RAT; TRABECULAR BONE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT BEARING; ANIMAL; ANIMAL BEHAVIOR; BONE TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; METASTASIS; NOCICEPTION; PAIN; PAIN ASSESSMENT; PATHOLOGY; RADIOGRAPHY; SPRAGUE DAWLEY RAT;

ANIMALS; BEHAVIOR, ANIMAL; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; FEMALE; MAGNETIC RESONANCE IMAGING; MALE; MAMMARY NEOPLASMS, ANIMAL; NOCICEPTION; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; TUMOR BURDEN; WEIGHT-BEARING; X-RAY MICROTOMOGRAPHY;

MLCS; MLOWN;

EID: 84875078699     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9530-0     Document Type: Article

References (74)

1. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11(6):411-425
2. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s-6249s
3. Suva LJ et al (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7(4):208-218
4. Jemal A et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
5. Trinkaus M et al (2009) Examination of the mechanisms of osteolysis in patients with metastatic breast cancer. Oncol Rep 21(5):1153-1159
6. Rove KO, Crawford ED (2009) Metastatic cancer in solid tumors and clinical outcome: skeletal-related events. Oncology 23(14 Suppl 5):21-27
7. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588-1594
8. Jensen AO et al (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29
9. van den Beuken-van Everdingen MH et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18(9):1437-1449
10. Kirou-Mauro AM et al (2009) Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. J Pain Symptom Manag 37(1):77-84
11. Paes FM et al (2011) Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J Support Oncol 9(6):197-205
12. Pacharinsak C, Beitz A (2008) Animal models of cancer pain. Comp Med 58(3):220-233
13. Jimenez-Andrade JM et al (2010) Bone cancer pain. Ann N Y Acad Sci 1198:173-181
14. Schwei MJ et al (1999) Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19(24):10886-10897
15. Mao-Ying QL et al (2006) A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun 345(4):1292-1298
16. Medhurst SJ et al (2002) A rat model of bone cancer pain. Pain 96(1-2):129-140
17. Zhang RX et al (2005) Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 118(1-2):125-136
18. Halvorson KG et al (2006) Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain 22(7):587-600
19. Bloom AP et al (2011) Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain 12(6):698-711
20. Jimenez-Andrade JM et al (2010) Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 30(44):14649-14656
21. Jimenez-Andrade JM et al (2011) Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain 152(11):2564-2574
22. Sabino MA et al (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62(24):7343-7349
23. Fox A et al (2004) Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain 107(1-2):33-40
24. Nagae M, Hiraga T, Yoneda T (2007) Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25(2):99-104
25. El Mouedden M, Meert TF (2007) The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. Pharmacol Biochem Behav 87(1):30-40
26. Sevcik MA et al (2004) Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111(1-2):169-180
27. Tripathy D, Body JJ, Bergstrom B (2004) Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 26(12):1947-1959
28. Jimenez Andrade JM, Mantyh P (2010) Cancer pain: from the development of mouse models to human clinical trials. Translational pain research: from mouse to man. Frontiers in Neuroscience. CRC Press, Boca Raton
29. Costelloe CM et al (2009) Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10(6):606-614
30. Houssami N, Costelloe CM (2012) Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol 23(4):834-843
31. Hsu WK et al (2008) Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT. J Nucl Med 49(3):414-421
32. Zitzmann-Kolbe S et al (2010) D-18F-fluoromethyl tyrosine imaging of bone metastases in a mouse model. J Nucl Med 51(10):1632-1636
33. Cheng C et al (2011) Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG. Hell J Nucl Med 14(1):15-20
34. Merz M et al (2011) Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer 47(2):277-286
35. Bauerle T et al (2010) Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res 16(12):3215-3225
36. Grankvist J et al (2012) MRI and PET/CT of patients with bone metastases from breast carcinoma. Eur J Radiol 81(1):e13-e18
37. Walkington L, Coleman RE (2011) Advances in management of bone disease in breast cancer. Bone 48(1):80-87
38. Coleman RE, McCloskey EV (2011) Bisphosphonates in oncology. Bone 49(1):71-76
39. Aapro MS, Coleman RE (2012) Bone health management in patients with breast cancer: current standards and emerging strategies. Breast 21(1):8-19
40. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
41. Doré-Savard L et al (2010) Behavioral, medical imaging and histological features of a new rat model of bone cancer pain. PLoS One 5(10):e13774
42. Tetreault P et al (2011) Weight bearing evaluation in inflammatory, neuropathic and cancer chronic pain in freely moving rats. Physiol Behav 104(3):495-502
43. Castaneda-Corral G et al (2011) The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience 178:196-207
44. Mercadante S, Fulfaro F (2007) Management of painful bone metastases. Curr Opin Oncol 19(4):308-314
45. Angst MS, Clark JD (2006) Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104(3):570-587
46. King T et al (2007) Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain 132(1-2):154-168
47. Hamaoka T et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22(14):2942-2953
48. Gauvain KM et al (2005) MRI detection of early bone metastases in b16 mouse melanoma models. Clin Exp Metastasis 22(5):403-411
49. Wang L et al (2008) MRI and hybrid PET/CT for monitoring tumour metastasis in a metastatic breast cancer model in rabbit. Nucl Med Commun 29(2):137-143
50. Kundra V et al (2007) In vivo imaging of prostate cancer involving bone in a mouse model. Prostate 67(1):50-60
51. Murakami K et al (2008) Correlation between high field MR images and histopathological findings of rat transplanted cancer immediately after partial microwave coagulation. Magn Reson Med Sci 7(3):105-112
52. Reichardt W et al (2009) Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. Invest Radiol 44(5):298-303
53. Rozel S et al (2009) Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem 107(1):58-64
54. Walker K et al (2002) Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain 100(3):219-229
55. Shah M et al (2012) An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS ONE 7(1):e29615
56. Holland PM et al (2010) Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 9(7):539-550
57. Svensson CI et al (2008) Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain. Pharmacol Biochem Behav 90(4):664-675
58. Ghilardi JR et al (2011) Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone 48(2):389-398
59. Mantyh WG et al (2010) Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience 171(2):588-598
60. Peters CM et al (2005) Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 193(1):85-100
61. Sevcik MA et al (2005) Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115(1-2):128-141
62. Kaan TK et al (2010) Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain 133(9):2549-2564
63. Ghilardi JR et al (2010) Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. Mol Pain 6:87
64. Zwolak P et al (2008) Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer 122(3):681-688
65. Hipp JA, Springfield DS, Hayes WC (1995) Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop Relat Res 312:120-135
66. El Mouedden M, Meert TF (2005) Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain. Pharmacol Biochem Behav 82(1):109-119
67. Tong Z et al (2010) Tumor tissue-derived formaldehyde and acidic microenvironment synergistically induce bone cancer pain. PLoS ONE 5(4):e10234
68. Yoneda T et al (2011) Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 48(1):100-105
69. Lipton A, Jacobs I (2011) Denosumab: benefits of RANK ligand inhibition in cancer patients. Curr Opin Support Palliat Care 5(3):258-264
70. Pantano F et al (2011) New targets, new drugs for metastatic bone pain: a new philosophy. Expert Opin Emerg Drugs 16(3):403-405
71. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6(3):163-174
72. Costa L et al (2011) Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol 77(Suppl 1):S31-S37
73. Zheleznyak A et al. (2011) Integrin alpha(v)beta (3) as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol Aug 19: 1-9
74. Lage MJ et al (2008) The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 14(5):317-322